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Abstract We examined neurocognitive functioning among
persons with acute or early HIV infection (AEH) and
hypothesized that the neurocognitive performance of AEH
individuals would be intermediate between HIV seroneg-
atives (HIV−) and those with chronic HIV infection.
Comprehensive neurocognitive testing was accomplished
with 39 AEH, 63 chronically HIV infected, and 38 HIV−
participants. All AEH participants were HIV infected for
less than 1 year. Average domain deficit scores were
calculated in seven neurocognitive domains. HIV−, AEH,
and chronically HIV infected groups were ranked from best
(rank of 1) to worst (rank of 3) in each domain. All
participants received detailed substance use, neuromedical,
and psychiatric evaluations and HIV infected persons
provided information on antiretroviral treatment and com-
pleted laboratory evaluations including plasma and CSF
viral loads. A nonparametric test of ordered alternatives
(Page test), and the appropriate nonparametric follow-up
test, was used to evaluate level of neuropsychological (NP)
functioning across and between groups. The median
duration of infection for the AEH group was 16 weeks
[interquartile range, IQR: 10.3–40.7] as compared to
4.9 years [2.8–11.1] in the chronic HIV group. A Page test
using ranks of average scores in the seven neurocognitive
domains showed a significant monotonic trend with the best
neurocognitive functioning in the HIV− group (mean rank=
1.43), intermediate neurocognitive functioning in the AEH
group (mean rank=1.71), and the worst in the chronically
HIV infected (mean rank=2.86; L statistic=94, p<0.01);
however, post-hoc testing comparing neurocognitive im-
pairment of each group against each of the other groups
showed that the chronically infected group was significant-
ly different from both the HIV− and AEH groups on
neurocognitive performance; the AEH group was statisti-
cally indistinguishable from the HIV− group. Regression
models among HIV infected participants were unable to
identify significant predictors of neurocognitive perfor-
mance. Neurocognitive functioning was worst among
persons with chronic HIV infection. Although a significant
monotonic trend existed and patterns of the data suggest the
AEH individuals may fall intermediate to HIV− and
chronic participants, we were not able to statistically
confirm this hypothesis.
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Introduction
Combined antiretroviral therapies (ART) have reduced
medical morbidity and mortality due to HIV although
neurological complications, especially HIV-associated
neurocognitive disorders (HAND), are still common.
Severe forms of HAND, such as HIV-associated demen-
tia, are less common in the ART era; however, recent
studies found that 30–50% of HIV-infected persons
receiving ART have milder HAND syndromes (Sevigny
et al. 2007; Tozzi et al. 2007) .T h ei m p o r t a n c eo f
understanding the consequences of HAND is substantial
as impairment can be associated with declines in everyday
functioning (Heaton et al. 2004b), employment (Heaton et
al. 1994), driving (Marcotte et al. 2006), and managing
medications (Woods et al. 2009a).
The reasons for the persistence of HAND are not well
understood. One possibility is that events during the acute
or early stages of HIV infection (AEH; i.e., between 0- and
52-weeks duration) may set the stage for neurological
disease during chronic infection, particularly since AEH is
characterized by high levels of HIV replication and organ
dissemination (Daar et al. 1991; Little et al. 1999; Schacker
et al. 1998), including to the central nervous system (CNS;
Tambussi et al. 2000). A preliminary international study
suggested that neurocognitive difficulties exist in the early
stages of HIV infection including impairments in speed of
information processing and verbal fluency (Mandal et al.
2008), and it is recognized that CNS involvement can occur
during ‘asymptomatic’ infection and may precede other
disease manifestations (Grant et al. 1987). Neuroimaging
studies have also suggested that there are brain alterations
early during HIV infection (Lentz et al. 2009) and a recent
study by our group suggested that HIV infection may result
in early changes to subcortical regions followed by spread
to cortical regions (Ances et al. 2009).
To date, there have been no reports comparing AEH and
chronically infected persons on comprehensive neurocogni-
tive testing. We examined groups of participants with AEH
and chronic infection, as well as HIV negative (HIV−)
controls with a standardized battery of neurocognitive tests
to ascertain whether there were specific neurocognitive
deficits in AEH and to compare such deficits to chronically
HIVinfected persons. Our working hypothesis was that there
would be a trend toward worse neurocognitive performance
such that HIV− would manifest the best performance,
followed by AEH and then chronically HIVinfected. We also
explored variables, e.g., viral load, nadir CD4, ART treatment
status, which might predict neurocognitive performance.
Methods
Study population
This study evaluated 39 participants with AEH infection,
63 participants with chronic infection, and 38 individuals
who were HIV−. Participants were collected from the
UCSD site of the NIH-funded CNS HIV Antiretroviral
Therapy Effects Research (CHARTER) study and the
UCSD HIV Neurobehavioral Research Center (HNRC).
Exclusion criteria included: (1) neurologic disorder not
related to HIV infection (e.g., stroke, uncontrolled seizure
disorder, head injury with loss of consciousness for longer
than 30 min), (2) current or past psychotic disorder (e.g.,
schizophrenia) not related to stimulant or other substance
use, (3) conditions that prevent use of consistent neuro-
cognitive testing (e.g., severe visual or hearing impair-
ment), and (4) participants less than 18 years of age. At the
time of neurocognitive testing, participants reported no use
of illicit substances in the past week (excluding marijuana)
and were required to have a negative toxicology screen.
The UCSD Human Research Protection Program ap-
proved the current study and all study participants provided
written informed consent to participate. At assessment, all
subjects completed a blood draw, neuromedical exam,
comprehensive neurocognitive testing, detailed substance
use history, structured psychiatric interviews for detecting
lifetime and current diagnoses of substance use disorders
and affective disorders, and a measure of current mood.
Laboratory measures included hemogram and routine blood
chemistries, plus determination of HIV viral load. Cerebro-
spinal fluid (CSF) studies (including viral load) were
completed with 33/39 AEH and 57/63 chronically infected
(see Table 1).
Participants in the AEH group had acute or early HIV
infection staged based on the Fiebig classification (Fiebig et
al. 2003) and duration of HIV Infection was estimated, as
previously described (Volberding et al. 2009), by evaluation
of the following data collected at the time of the neuro-
cognitive evaluation, unless otherwise noted: (1) detectable
HIV-1 RNA (Amplicor, Roche) and HIV enzyme immuno-
assay (EIA) negative, or (2), HIV RNA positive and
Western Blot indeterminate with no more than three
positive bands or alternatively, (3) an HIV RNA positive,
EIA positive and detuned EIA consistent with very recent
infection of <133 days (OD≤0.75 by Vironostika, or
equivalent by Vitros ECi or OraQuick detuned) (Kothe et
al. 2003), or (4) a known last negative EIA, followed by a
known positive EIA and neurocognitive assessment within
182 days of the last known EIA negative test.
Participants in the chronic HIV (CH) group were
estimated to have HIV infection for more than 1 year at
their neurocognitive assessment as defined by the time from
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known positive EIA occurring intermediate to these two
time points). For participants using this latter approach
(AEH criterion #4 and chronic HIV criterion), estimated
duration infection was calculated from the last known
negative test to guard against underestimating duration of
HIV infection. The HIV− and chronic HIV participants
were selected from a pool of existing participants to be as
comparable as possible to the AEH group on demographic
(both HIV− and chronic HIV groups), lifetime substance
abuse or dependence (both HIV− and chronic HIV groups)
and HIV disease (chronic HIV group only) factors
(although not possible for all variables) blinded to neuro-
cognitive outcomes.
Neurobehavioral and psychiatric examinations
All participants completed a comprehensive neuropsycholog-
ical test battery that assessed seven domains (i.e., verbal
fluency, executive functioning, speed of information process-
ing, learning, recall, working memory, and motor skills), as
previously described (Woods et al. 2004;H e a t o ne ta l . ,
in press). Raw test scores were converted to demographically
adjusted T-scores using up-to-date normative data (Cherner
et al. 2007;H e a t o ne ta l .2004a;H e a t o ne ta l .2003). T-
scores were converted into deficit scores ranging from 0 (T-
score>39; no impairment) to 5 (T-score<20; severe impair-
ment). The deficit scores were then averaged to derive a
Global Deficit Score (GDS), which reflected both the
number and the severity of deficits across the neuropsycho-
logical battery (Carey et al. 2004;H e a t o ne ta l .2004a;
Heaton et al. 1995). We also calculated domain deficit scores
for each of the seven neurocognitive domains and ranked
performance in each of these domains across groups (HIV−,
AEH, Chronic) on a simple 1 (best neurocognitive perfor-
mance) to 3 (worst neurocognitive performance) scale.
Structured mood disorder and substance abuse/depen-
dence diagnoses were obtained using the Composite
Table 1 Demographic, substance use, psychiatric, and HIV disease characteristics for the groups
Demographics HIV− (N=38) AEH (N=39) Chronic (N=63) P value Difference
Age, years; mean (SD) 32.5 (9.2) 31.9 (8.4) 34.5 (5.4) 0.17
Education, years; mean (SD) 13.8 (2.4) 14.4 (2.1) 13.6 (2.6) 0.23
Male 32 (84%) 36 (92%) 58 (92%) 0.42
Caucasian 25 (66%) 27 (69%) 37 (59%) 0.53
WRAT-III Reading Score, Raw; mean (SD) 50 (5.0) 50 (4.1) N=37 49 (4.6) N=60 0.68
Infected with hepatitis C 2 (5%) 0 (0%) 6 (10%) 0.15
Substance abuse/dependence
Alcohol (lifetime) 14 (37%) 17 (44%) 38 (60%) 0.05
Marijuana (lifetime) 13 (34%) 11 (28%) 23 (37%) 0.68
Methamphetamine (lifetime)
a 16 (42%) 16 (41%) 24 (38%) 0.91
Cocaine (lifetime) 5 (13%) 9 (23%) 21 (33%) 0.06
Opioid (lifetime) 0 (0%) 4 (10%) 7 (11%) 0.08
Psychiatric
Major depressive disorder (lifetime) 7 (18%) 19 (50%) N=38 31 (49%) 0.003 HIV−<AEH, CH
Major depressive disorder (current) 2 (5%) 3 (8%) 6 (10%) 0.92
Beck Depression inventory-II
a; mean (SD) 6.3 (8.3) 10.0 (8.1) 13.0 (10.0) 0.002 HIV−<CH
HIV disease characteristics
CD4 count; mean (SD) N/A 538 (287) 570 (299) 0.60
Nadir CD4; mean (SD) N/A 386 (185) 294 (225) 0.04 AEH>CH
Plasma viral load (log10)
a; median (IQR) N/A 4.5 (3.1–5.0) 2.3 (1.7–4.3) <0.0001 AEH>CH
Detectable plasma viral load
a N/A 37 (95%) 37 (59%) <0.0001 AEH>CH
CSF viral load (log10); median (IQR) N/A 2.3 (1.7–3.4) N=33 1.7 (1.7–2.9) N=57 0.11
Detectable CSF viral load N/A 21 (64%) N=33 22 (39%) N=57 0.02 AEH>CH
Peak plasma viral load (log10); median (IQR) N/A 5.1 (4.8–5.7) N=36 4.9 (4.4–5.3) N=55 0.41
Duration of infection (weeks); median (IQR) N/A 16 (10–41) 255 (144–579) <0.0001 AEH<CH
ART status (on)
a N/A 6 (15%) 36 (57%) <0.0001 AEH<CH
Values are shown as N (%) unless indicated otherwise
aCandidates considered in model selection based on p<0.10 criterion for association between variable and Global Deficit Score
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and mood symptoms were evaluated with the Beck
Depression Inventory-II (Beck et al. 1996). Abuse and
dependence were evaluated separately for alcohol, marijua-
na, cocaine, methamphetamine, and opioid substance
groups. To decrease the number of statistical comparisons,
participants were collapsed into lifetime and past month
abuse/dependence for each of the five substances.
Neuromedical examination
We performed a comprehensive neuromedical evaluation
that included past and current ART use, a structured
neurological and medical examination, and collection of
blood and urine samples. For those who consented, CSF
was collected by lumbar puncture. HCV serostatus was
evaluated by standard clinical antibody detection [ADVIA
Centaur XP Immunoassay, Siemens Healthcare Diagnos-
tics], and confirmed for active HCV infection by measuring
HCV RNA (Roche Amplicor HCV Monitor Test, nominal
detection limit of 28 IU/mL).
Statistical analysis
Descriptive summaries of study groups were reported as
mean (SD), median (interquartile range (IQR)), and N
(%). Prior to all statistical testing, the data, either raw or
transformed, were reviewed to ensure that test assump-
tions were valid. Univariable comparisons of demograph-
ic, substance abuse/dependence, psychiatric, and
neurobehavioral variables among the HIV−,A E H ,a n d
chronic HIV groups were performed using ANOVA,
Welch’s t tests, Chi-square tests, and Fisher Exact tests,
depending on the type of data and assumption validity.
Among variables found to be significant, pairwise com-
p a r i s o nw a sp e r f o r m e dw i t hT u k e y ’s HSD test or logistic
regression. The same methods were used to analyze
differences in HIV disease characteristics between the
AEH and chronic infection groups.
To test the overall hypothesis that there would be a
monotonic trend in neurocognitive data such that perfor-
mance would be ordered as HIV− (best), AEH (intermedi-
ate), and chronically infected (worst), we used the Page test
for ordered alternatives. A Page test determined if the
medians of mean domain deficit scores monotonically
increased in the groups ordered by hypothesized risk (Page
1963). If the Page test produced significant results, pairwise
comparisons were performed using a multiple comparison
technique adapted from the Friedman two-way ANOVA by
ranks test (Siegel and Castellan 1988) that controls the
overall 5% Type I error rate. Tests were one-sided,
consistent with our hypothesis, and based on a 5%
significance level.
In addition, to explore how group membership and
other variables, including demographic and HIV disease
characteristics, were related to neurocognitive function-
ing, we performed a series of linear regression analyses
within HIV+ persons. Included in the analyses were potential
confounder variables, defined as univariable predictors of
GDS with p values<0.10. Spearman rank correlation tests
were applied to the continuous potential confounder varia-
bles, and those with significant correlation among them-
selves were not included together in a model. To control for
the potential interaction of ART use and viral load, current
ART status (on/off) was added to models that included
plasma viral load, and their interactions were tested. By
process of forward–backward stepwise regression (based on
Akaike Information Criterion), each model was reduced to
its most simple form (Akaike 1974). We forced the primary
variable of interest (AEH vs. CH) into all models.
Results
The sample consisted predominantly of Caucasian men in
their early 30s who had some college education. AEH
participants were demographically comparable to chronic
HIV and HIV− participants (Table 1). As might be
expected, lifetime rates of major depression and substance
use disorders were high in HIV+ individuals, while current
(1 month) rates of substance use disorders were much
lower. There were no significant differences across groups
in lifetime rates of substance abuse/dependence, and rates
of past month abuse/dependence of other substances were
rare and comparable across groups (e.g., the highest rate of
abuse/dependence was that 8% of HIV− group had used
marijuana in the past month). In terms of psychiatric
characteristics, both HIV+ groups evidenced a significant-
ly higher lifetime prevalence of major depressive disorder
(MDD) diagnosis, when compared to the HIV− group, but
there were no differences in current MDD rates. The
chronic HIV infection group reported significantly higher
depressive symptoms scores on the Beck Depression
Inventory-II than the HIV− group (p=0.002). Rates of
HCV infection were low (0–10%). In terms of HIV disease
characteristics, AEH had an estimated duration of infec-
tion of about 4 months as compared to over 4 years for the
chronically infected. Whereas the groups were comparable
on current CD4 counts, the chronic group reported
significantly lower CD4 nadir counts (Table 1). At the
same time, plasma viral loa dw a sh i g h e ri nA E Ha n di s
consistent with the fact that only 15% (versus 57% for the
chronically infected) were on ART at time of examination.
CSF viral loads were comparable between groups. Pro-
portions of subjects with detectable plasma viral load and
CSF viral load were significantly lower for the CH group
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characteristics for the AEH and chronic HIV groups.
To test the hypothesis that the AEH participants would
manifest more neurocognitive difficulties than uninfected
controls, but fewer than those with chronic HIV infection,
the average domain deficit scores for each of the seven
neurocognitive domains were ranked 1 (best group perfor-
mance) through 3 (worst group performance) in order to
apply a Page test for ordered alternatives. The Page test was
significant (p<0.01), indicating the presence of a mono-
tonically increasing trend in deficits among the three groups
in the order of HIV− (mean rank=1.43), AEH (mean rank=
1.71), and chronically HIV infected (mean rank=2.86;
L statistic=94). In follow-on pairwise comparisons, HIV−
and the AEH groups were different from the chronically
infected group on neurocognitive performance. Although
appearing intermediate, the performance of the AEH group
did not differ significantly from HIV−.
The results of neurocognitive testing by domain are
p r e s e n t e di nF i g .1. The majority of neurocognitive
domains (five of seven: executive functioning, speed of
information processing, learning, recall, and working
memory), as well as global neurocognitive functioning,
show a “stair step” pattern where performance is consistent
with the hypothesized direction.
A series of linear regressions were performed to model
overall level of neurocognitive functioning and determine
predictors of performance among AEH and CH groups. The
variables that were entered into the model are marked by
superscript “a” in Table 1 and demographic, substance use,
psychiatric, and HIV disease variables were considered.
Wide Range Achievement Test, Third Edition (WRAT-III)
Reading score was significantly associated with GDS on a
univariable basis (p=0.01); however, given that the WRAT-
III Reading Test is a neuropsychological test, and would be
assumed to have some association with overall neuro-
cognitive functioning, we chose to not include this variable
in our predictive models.
In a model that included all HIV+ participants, there were
no significant predictors of neurocognitive functioning.
Discussion
In this study, neurocognitive performance was worst among
chronically HIV-infected participants as was expected;
while the performance of AEH persons trended to fall
intermediate between chronically infected and uninfected,
we were not able to statistically confirm neurocognitive
impairment differences between the AEH individuals and
HIV-uninfected persons. In this particular cohort, no
specific HIV disease indicators were associated with the
presence of neurocognitive impairment. There are several
possible explanations for the lack of an observable
intermediate neurocognitive profile for the AEH group.
The first possible explanation is that there are no
significant neurobiologic changes early in HIV infection
and therefore no neuropsychological impairments. This
explanation seems unlikely given that neuroimaging evi-
dence among AEH participants suggests some neurobio-
logic alterations. Specifically, an arterial spin labeling study
reported reductions in regional cerebral blood flow oc-
curred soon after seroconversion; and may possibly reflect
neuronal or vascular injury among individuals not yet
expressing neurocognitive impairment (Ances et al. 2009).
Another recent magnetic resonance spectroscopy study
demonstrated neuronal injury or loss (i.e., reduction in N-
acetyl aspartate and glutamate+glutamine levels) among
AEH participants who presented with seroconversion
illness but no neurologic symptoms (Lentz et al. 2009).
The above imaging studies suggest that at least subtle
neurobiologic changes are occurring in the earliest phases
of HIV infection but that these neurobiologic changes might
not be significant enough to produce observable changes in
neurocognitive outcomes. Alternatively, it may be that the
observable neurocognitive changes are only evidenced
during a specific window when HIV is actively disrupting
neurobiologic mechanism; as such, subtle neurocognitive
changes at this early stage may be transient and difficult to
capture at a moment in time.
Finally, it seems equally plausible that the subtle neuro-
biologic changes result in mild neurocognitive problems
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statistically captured in a study with a relatively small sample
size such as the study we provide here. The non-significant
general pattern toward intermediate neurocognitive function
for the AEH group (as compared to other two groups) was
observed on a global measure, and for five of seven ability
domains(Fig.1), and speaks to this latter possibility. The fact
that intermediate indications were most frequently observed
in domains that prior research has identified as being
particularly sensitive to HIV effects including executive
functioning and various aspects of memory (including
learning, recall, and working memory) is also supportive of
a mild intermediate effect that was not statistically observ-
able here (Reger et al. 2002). The domain of speed of
information processing also reflected a tendency toward
increasing cognitive difficulties among AEH as compared to
HIV− individuals, consistent with previously reported prob-
lems in attentional abilities and rapid processing of complex
information that have been associated with more advanced
HIV disease (Woods et al. 2009b).
The literature has previously suggested some possible
mechanisms that may result in the early, subtle changes in
neurocognitive performance. The hallmarks of AEH are
high levels of HIV replication and wide dissemination of
virus, including to the CNS. Replication peaks could lead to
neuronal injury by increasing the production of virions and
HIV encoded proteins in the CNS. These processes might
be facilitated by increasing systemic response and neuro-
inflammation, which could be accompanied by injury to the
blood–brain-barrier. Recent data supporting these possibil-
ities found that worse performance on select neurocognitive
measures by AEH participants was associated with higher
levels of CSF MCP-1 and IP-10, suggesting monocyte and
CD8 T cell activation in the CNS (Peterson et al. 2010).
Our finding that there were no significant predictors of
neurocognitive performance in this study speaks to the
need to continue to investigate and understand the
possible mechanisms responsible for neurocognitive
changes among HIV-infected persons. Although the
present study is the largest of its kind in terms of
comparing AEH, CH, and HIV− groups with a compre-
hensive neurocognitive battery, group sizes are still
relatively small and the study may not be sufficiently
powered to detect predictors of functioning. In order to
minimize differences between groups, we matched our
CH group with our AEH group on demographic,
substance use, mood, and HIV disease characteristics,
and one consequence was that our overall HIV group
was primarily male, Caucasian, and had relatively high
education levels that may not be representative of the
wider HIV-infected population. Therefore, it may be
more difficult for subtle NP impairments to be observed
in this study as more educated populations may have
higher levels of cognitive reserve (Stern 2009). The
alternative hypothesis that there is no neurobiological
effect strong enough to be neurocognitively detected
regardless of cognitive reserve level is also plausible.
Importantly, the observation that AEH participants are not
statistically different from HIV− persons in NP impair-
ment rates argues against the hypothesis that pre-existing
comorbidities are the primary source of impaired NP
performance among HIV-infected persons.
It is important that future research follow-up on
mechanisms investigated herein with a larger cohort and
longitudinal studies (including a neuroimaging component)
of persons transitioning through the first weeks and months
of HIV infection, and in particular, to link these possible
mechanisms to initiation of ART treatment. Another
important avenue for future research would be to explore
the effects of early initiation of ART with various CNS
penetrating capabilities on both neurocognitive outcomes,
and potential mediators of neurocognitive change, such as
CNS HIV replication, and inflammatory markers.
In summary, neurocognitive functioning is most signif-
icantly impacted among the chronically infected. Our study
was unable to statistically confirm neurocognitive impair-
ments in the earliest stage of HIV infection, but there is a
pattern toward, and non-statistical indicators of, AEH
persons showing neurocognitive performance intermediate
to HIV− controls and persons with chronic HIV. There are
many potential hypotheses for our pattern of results ranging
from the lack of a distinct neurobiologic effect to cause
neurocognitive changes in the AEH to an inability to detect
subtle neurocognitive changes because of power. Because
of previous evidence pointing to subtle neurobiologic
changes early in disease, we believe that future studies of
AEH, particularly those contemplating clinical trials with
early ART treatment, should include neurocognitive and
neuroimaging measures both to document the potential
CNS effects of such interventions and to assess for how
they modify neurobiologic and neurocognitive outcomes.
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